Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference
November 11, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel...
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
November 09, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
3Q21 Total Galafold® Revenue of $79.5M – an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance of $300M-$315M AT-GAA BLA and NDA for Pompe Disease Accepted for Review by the...
Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021
November 03, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 9, 2021 at...
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”
September 29, 2021 06:30 ET
|
Amicus Therapeutics, Inc.
Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding ...
U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease
September 29, 2021 06:30 ET
|
Amicus Therapeutics, Inc.
FDA Sets PDUFA Target Action Date of May 29, 2022 for the New Drug Application and July 29, 2022 for the Biologics License Application On Track for MAA Submission in the Fourth Quarter of this Year ...
Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society
September 20, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2021
September 03, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at...
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
August 05, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
2Q21 Total Galafold® (migalastat) Revenue of $77.4M, a 24% increase over 2Q20 On-Track to Achieve Revenue Guidance of $300M-$315M Completed the Rolling BLA and NDA Submissions to the U.S. FDA for...
Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 04, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG...
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
August 02, 2021 07:00 ET
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines...